Who
Michael Andrew Chambers
Director
Company insider
Files Form 4 as: Director, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 6
- Sells
- 0
- Bought
- $23.3M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Jun 2022
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,875 | filing |
| 18 Dec 2025filed 19 Dec 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | — | filing |
| 18 Dec 2025filed 19 Dec 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | — | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,792 at $0.00 | filing |
| 10 Mar 2025filed 11 Mar 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,383 | filing |
| 16 Aug 2024filed 20 Aug 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.7M13,106 at $133.07 | filing |
| 16 Aug 2024filed 20 Aug 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.5M18,284 at $134.06 | filing |
| 16 Aug 2024filed 20 Aug 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $761K5,648 at $134.66 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,679 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,846 at $0.00 | filing |
| 14 Aug 2023filed 15 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $649K5,947 at $109.19 | filing |
| 14 Aug 2023filed 15 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $443K4,032 at $109.89 | filing |
| 11 Aug 2023filed 14 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.6M23,686 at $108.05 | filing |
| 10 Aug 2023filed 11 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $231K2,206 at $104.67 | filing |
| 10 Aug 2023filed 11 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $116K1,091 at $105.90 | filing |
| 10 Aug 2023filed 11 Aug 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.4M31,570 at $106.26 | filing |
| 6 Mar 2023filed 8 Mar 2023 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,257 at $0.00 | filing |
| 6 Mar 2023filed 8 Mar 2023 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,523 at $0.00 | filing |
| 14 Sep 2022filed 15 Sep 2022 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.2M20,744 at $103.87 | filing |
News
Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)SRPT · dailypolitical.com · 22 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Michael Andrew Chambers; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.